Treatment with the novel oral selective estrogen receptor degrader camizestrant significantly improves progression-free survival versus fulvestrant in patients with pretreated, estrogen receptor-positive, HER2-negative advanced breast cancer, shows a phase 2 study.

Ribociclib plus endocrine therapy is associated with a significant progression-free survival benefit relative to combination chemotherapy in treatment-naïve patients with hormone receptor-positive, HER2-negative, advanced breast cancer with aggressive features, suggest trial data.

The addition of the AKT inhibitor capivasertib to fulvestrant significantly prolongs the progression-free survival of people with hormone receptor-positive, HER2-negative advanced breast cancer that is resistant aromatase inhibitors, indicate the results of CAPItello-291.

Among people with endocrine-resistant, hormone receptor-positive, HER2-negative advanced breast cancer, sacituzumab govitecan is associated with significantly improved overall survival relative to standard of care, show data from TROPiCS-02.

Hope Rugo outlines the latest results from the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor-positive, HER2-negative advanced breast cancer and discusses where the antibody–drug conjugate fits into the treatment paradigm.

Dalpiciclib given in combination with an aromatase inhibitor offers a novel first-line treatment option for patients with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer, say the DAWNA-2 investigators.

medwireNews : ASCO has released updates to its guidelines for systemic therapy and the management of brain metastases in advanced HER2-positive breast cancer as well as for the use of biomarkers to guide systemic therapy in metastatic breast cancer.

PALOMA-2 study findings suggest that first-line palbociclib does not improve overall survival when added to letrozole for estrogen receptor-positive, HER2-negative advanced breast cancer, but the analysis was hindered by missing data.

Sacituzumab govitecan offers a significant progression-free survival  benefit over standard treatment in patients with endocrine-resistant, hormone receptor-positive, HER2-negative advanced breast cancer, according to phase 3 trial data.

medwireNews : The antibody–drug conjugate fam-trastuzumab deruxtecan-nxki has received regular approval from the US FDA for the treatment of HER2-positive advanced breast cancer.

Exploratory analyses from the MONALEESA-3 trial after more than 5 years of follow-up show that first-line use of ribociclib alongside fulvestrant continues to offers a significant overall survival benefit versus fulvestrant alone in patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Circulating tumor DNA target mutations may represent a promising prognostic biomarker among women receiving first-line ribociclib plus letrozole for hormone receptor-positive, HER2-negative advanced breast cancer, research suggests.

The novel CDK4/6 inhibitor dalpiciclib plus fulvestrant could be “a new treatment option” for patients who have received prior endocrine therapy for hormone receptor-positive advanced breast cancer, say the DAWNA-1 investigators.

Supplementing fulvestrant with alpelisib does not adversely affect the health-related quality of life of patients with PIK3CA -mutated, hormone receptor-positive, HER2-negative, advanced breast cancer, indicate SOLAR-1 trial findings.

Treatment with the novel HER2-targeted agent margetuximab improves the outcomes of heavily pretreated patients with HER2-positive advanced breast cancer, indicate phase 3 trial results.

Combined treatment with durvalumab plus bevacizumab could benefit women with HER2-negative advanced breast cancer who have progressed on bevacizumab maintenance, shows a phase 1b trial.

Supplementing capecitabine with neratinib instead of lapatinib is associated with a significant improvement in the progression-free survival of previously treated patients with metastatic HER2-positive breast cancer, shows the phase 3 NALA trial.

medwireNews : The EMA has adopted a positive opinion for the use of alpelisib alongside fulvestrant in patients with locally advanced and metastatic breast cancer with an activating PIK3CA mutation.

medwireNews : The US FDA has approved the use of tucatinib  as a second-line or later treatment for patients with advanced unresectable or metastatic HER2-positive breast cancer.

Women with hormone receptor-positive, HER2-positive locally advanced, metastatic, or recurrent breast cancer might benefit from a third- or later-line regimen of the CDK4/6 inhibitor abemaciclib in combination with trastuzumab and fulvestrant, findings from the phase 2 monarcHER trial suggests.